Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Obtains CE-IVD Mark on NeuMoDx Epstein-Barr Virus, Human Herpesvirus-6 Tests

NEW YORK – Qiagen announced on Thursday that it has obtained the CE-IVD mark for RT-PCR assays to detect and quantify Epstein-Barr virus and human herpesvirus-6 on its NeuMoDx instruments. They are now available in the EU and countries that accept the CE marking for the NeuMoDx 96 and 288 automated molecular systems.

The EBV and HHV-6 tests are used for viral load monitoring for the management of immunocompromised people, such as organ transplant patients.

The NeuMoDx systems use microfluidic cartridges and provide results in one hour, with up to eight hours of walkaway time, Qiagen said in a statement. The two new tests expand the CE-IVD menu on the NeuMoDx systems to 16 assays, the firm further noted.

Qiagen is also developing an improved multiplex assay for influenza A and B, respiratory syncytial virus, and SARS-CoV-2 that will use a new dual-target SARS-CoV-2 design, as well as a multiplex research-use assay for the detection of monkeypox to be made available later this year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.